Lixivaptan
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Kidney Disease, Adult
Conditions
Polycystic Kidney Disease, Adult, ADPKD
Trial Timeline
Sep 2, 2020 → Jul 29, 2022
NCT ID
NCT04152837About Lixivaptan
Lixivaptan is a phase 3 stage product being developed by Centessa Pharmaceuticals for Polycystic Kidney Disease, Adult. The current trial status is terminated. This product is registered under clinical trial identifier NCT04152837. Target conditions include Polycystic Kidney Disease, Adult, ADPKD.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05208866 | Phase 3 | Terminated |
| NCT04152837 | Phase 3 | Terminated |
Competing Products
20 competing products in Polycystic Kidney Disease, Adult